| Popis: |
Objective: Radiotherapy (RT) is the first choice in the treatment of nasopharyngeal carcinoma, but there are many adverse reactions. There is evidence that Aidi injection can improve the effect of radiotherapy and reduce the occurrence of adverse reactions after radiotherapy, but there is still a lack of evidence-based studies. The objective of this study was to evaluate the efficacy and safety of Aidi injection combined with radiotherapy in the treatment of nasopharyngeal carcinoma. Methods: The PubMed, Cochrane Library, CNKI, EMBASE, Web of Science, CBM, Wanfang, and VIP Data were thoroughly searched for randomized controlled trials (RCTs) on Aidi injection combined with radiotherapy against nasopharyngeal carcinoma until February 2021. The literatures were screened, extracted, and evaluated by two investigators, independently. Meta-analysis was performed by RevMan5.3 and Stata 14.0, and GRADE for evaluating the evidence quality. Results: In this study, we included nine RCT studies involving 422 patients. The results showed significant between-group differences in complete remission rate (CRR) [RR=1.17, 95% CI (1.04, 1.31), P=0.009], KPS score[RR=1.30, 95% CI (1.19, 1.42), P 0.05], thrombocytopenia [RR=0.78, 95%CI (0.52,1.16), P=0.22 > 0.05], and skin injury [RR=0.81, 95%CI (0.64, 1.04), P= 0.1> 0.05]. Conclusion: Aidi injection combined with radiotherapy can improve patients' quality of life（KPS score）and reduce the adverse reactions caused by radiotherapy（such as leukopenia, hemoglobin reduction，oropharyngeal mucosa injury，nausea and vomiting）. However, due to limitations on the quality and numbers of the trials，more high-quality studies should be performed to verify our conclusions. |
